There are at least 200 distinct types of cancer, with many additional subtypes pushing that number far higher depending on how you count. The answer isn’t as simple as a single figure because cancer classification has become increasingly detailed over the past two decades. What was once called “lung cancer” or “breast cancer” is now understood to be a collection of biologically different diseases that happen to start in the same organ.
The Five Major Categories
Every cancer falls into one of five broad groups based on the type of tissue where it originates:
- Carcinomas start in the skin or the tissues that line organs. These are by far the most common cancers, including breast, lung, colon, and prostate cancers.
- Sarcomas develop in bone, cartilage, fat, muscle, or other connective tissues.
- Leukemias are cancers of the blood-forming tissues, primarily the bone marrow, and result in abnormal blood cells flooding the bloodstream.
- Lymphomas begin in the immune system, specifically in the lymph nodes and lymphatic tissue.
- Myelomas originate in plasma cells, a type of white blood cell found in bone marrow.
These five categories are the top level of a classification tree that branches rapidly once you start looking at specific organs, cell types, and genetic features.
Why One Cancer Is Really Many
Lung cancer illustrates how quickly the numbers multiply. At the broadest level, it splits into two main types: small cell and non-small cell. Non-small cell then divides further into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The most recent WHO classification, published in 2021, added even more distinct tumor types within the lung, including pulmonary myxoid sarcoma, bronchiolar adenoma, and a category of neuroendocrine tumors that itself contains several variants.
Each of these subtypes can behave differently, respond to different treatments, and carry a different prognosis. Two people both told they have “lung cancer” may have diseases that share very little at the molecular level. The same pattern holds for breast cancer, brain tumors, leukemias, and nearly every other organ site. Breast cancer alone includes at least a dozen recognized subtypes based on hormone receptor status, growth signals, and genetic mutations.
How Cancers Are Officially Counted
The global standard for classifying tumors is the WHO Classification of Tumours, sometimes called the “Blue Books.” This series, now in its 5th edition with some volumes already releasing 6th editions for breast and digestive tumors, catalogs every recognized tumor type across every organ system. Each volume runs hundreds of pages and defines tumors by how their cells look under a microscope, what proteins they produce, and what genetic changes drive them.
For cancer registries and medical records, a coding system called ICD-O (International Classification of Diseases for Oncology) assigns each tumor two codes: one for where it started in the body (topography) and one for what the cells look like (morphology). The morphology list alone contains hundreds of distinct codes. When you combine location and cell type, the number of unique cancer diagnoses stretches into the thousands.
This is why you’ll see different numbers depending on the source. The “200-plus” figure refers to broadly defined cancer types. The coding systems used by hospitals and registries recognize many more. Neither number is wrong; they’re just measuring at different levels of detail.
Rare Cancers Make Up a Large Share
A cancer is considered rare in the United States if it affects fewer than 40,000 people per year. By that definition, the vast majority of the 200-plus recognized cancer types are rare. Common cancers like breast, prostate, lung, and colorectal cancer get most of the attention and research funding, but collectively, rare cancers affect a significant portion of all cancer patients.
Many rare cancers are subtypes that were only recently split off from a broader category. A tumor once grouped under “soft tissue sarcoma” might now be recognized as a specific entity with its own name, genetic signature, and treatment approach. This reclassification is a sign of progress, but it also means patients with rare cancers often face fewer treatment options and longer paths to diagnosis.
Genetic Profiling Is Redefining Cancer Types
The biggest shift in cancer classification over the past decade is the move toward defining tumors by their genetic mutations, not just the organ where they appear. A landmark NIH project that analyzed the genomes of 33 cancer types found that tumors from different organs sometimes share the same molecular drivers, while tumors from the same organ can be genetically unrelated.
This matters practically. Treatments that target a specific genetic mutation can sometimes work across cancer types. A drug designed for a mutation common in skin cancer might also shrink a lung tumor carrying the same mutation. Clinical trials have followed this shift: the share of early-phase cancer trials using genetic matching rose from about 10% to over 28% in recent years, and response rates in those genetically matched trials reached roughly 29%. Comprehensive genetic profiling is now used in over 80% of early-phase oncology trials, up from 44% just a few years ago.
For patients, this means the question “What type of cancer do I have?” increasingly has two answers: the traditional one based on where the cancer started, and a molecular one based on what’s driving it. Both matter for treatment decisions, and both keep expanding the total count of meaningfully different cancer types.